GlassScriptPhysician profile
Genaro Paz
NPI 1326841263
$1,936.51
in general payments reported to CMS, 2019-2025
36 companies · $1,937 in 2025
The $1,937 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.51 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $293.41 | 2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $179.00 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $138.94 | 2025 | Xospata, Padcev, Vyloy |
| Beone Medicines USA, INC. | $108.52 | 2025 | Tevimbra, Brukinsa |
| Astrazeneca Pharmaceuticals LP | $86.76 | 2025 | Calquence, Tagrisso, Imfinzi |
| Genzyme Corporation | $65.28 | 2025 | |
| Legend Biotech USA INC. | $62.35 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $61.92 | 2025 | Xermelo |
| Exelixis INC. | $57.73 | 2025 | Cabometyx |
| Caris Mpi, INC. | $54.24 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $51.95 | 2025 | Jakafi, Niktimvo |
| Pfizer INC. | $51.58 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $50.81 | 2025 | Lynozyfic, Libtayo |
| Geron Corporation | $50.20 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $49.58 | 2025 | Ogsiveo, Gomekli |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.16 | 2025 | Datroway |
| Array Biopharma INC | $43.44 | 2025 | Braftovi, Lorbrena, Mektovi |
| Glaxosmithkline, LLC. | $42.61 | 2025 | Blenrep, Ojjaara |
| Adaptive Biotechnologies Corporation | $42.37 | 2025 | Clonoseq |
| Eisai INC. | $39.20 | 2025 | |
| Avyxa Pharma, LLC | $29.65 | 2025 | |
| Iovance Biotherapeutics, INC. | $29.00 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $28.91 | 2025 | |
| Novocure INC. | $27.99 | 2025 | Optune Gio |
| Takeda Pharmaceuticals U.S.A., INC. | $26.84 | 2025 | Ninlaro |
| Tempus Ai, INC | $26.83 | 2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $26.12 | 2025 | Besremi |
| Genentech USA, INC. | $24.43 | 2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $23.94 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.70 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $18.62 | 2025 | Danziten |
| Adc Therapeutics America, INC. | $17.35 | 2025 | |
| Sobi, INC | $16.58 | 2025 | |
| Recordati_rare_diseases_inc. | $14.79 | 2025 | Enjaymo |
| Lilly USA, LLC | $14.68 | 2025 | Verzenio, Jaypirca |
| Abbvie INC. | $14.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genaro Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.